Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q3 2023 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick toward a different part of the business that is already earning today, and indicates the record hasn't caught up. Let me analyze the transcript. The company is COMPASS Pathways, a psychedelics company developing COMP360 (psilocybin) for treatment-resistant depression. The conventional yardstick for this company would be its clinical pipeline, Phase III trials, and drug development progress. Looking at the call, management discusses: - Phase III trials (COMP005, COMP006) - on track - PTSD study - fully recruited - Anorexia study - Financial results - Cash position The key part of the call that might relate to the question is the discussion about Spravato (esketamine) sales and the infrastructure of interventional psychiatry facilities. Kabir Nath says: "we also continue to see strong esketamine sales sold under the brand name Spravato, which achieved global sales of $183 million this quarter, an increase of 82% compared to the third quarter of last year. This puts Spravato on a run rate of well over $600 million for 2023, continuing to demonstrate the unmet need in TRD. We believe this growth continues to be an important driver for the infrastructure of interventional psychiatry facilities and other treatment centres that we expect will be capable of delivering COM360 treatment, if approved." So management is pointing to Spravato sales as evidence of the growing infrastructure that could deliver COMP360. But is this "a different part of the business that is already earning"? Spravato is Johnson & Johnson's product, not COMPASS's. COMPASS is pointing to it as a market signal, not as its own earning business. The question asks about management redirecting attention away from the conventional yardstick (COMPASS's own pipeline/results) toward a different part of the business that is already earning. But Spravato is not COMPASS's business - it's a competitor's product. Management is using it as evidence of market demand and infrastructure development, not as an alternative revenue source for COMPASS. COMPASS's own business is entirely clinical-stage - it has no approved products, no revenue. The call is organized around its clinical programs, which is the conventional yardstick for a biotech with no commercial products.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.